Simchol

Simchol may be available in the countries listed below.

Ingredient matches for Simchol

Simvastatin

Simvastatin is reported as an ingredient of Simchol in the following countries:

• Indonesia

International Drug Name Search

Oxacilline

Oxacilline may be available in the countries listed below.

Ingredient matches for Oxacilline

Oxacillin

Oxacilline (DCF) is known as Oxacillin in the US.

International Drug Name Search

Glossary

DCF	Dénomination Commune Française

Click for further information on drug naming conventions and International Nonproprietary Names.

Liotixil

Liotixil may be available in the countries listed below.

Ingredient matches for Liotixil

Ceftazidime

Ceftazidime pentahydrate (a derivative of Ceftazidime) is reported as an ingredient of Liotixil in the following countries:

• Italy

International Drug Name Search

Varimer

Varimer may be available in the countries listed below.

Ingredient matches for Varimer

Mercaptopurine

Mercaptopurine monohydrate (a derivative of Mercaptopurine) is reported as an ingredient of Varimer in the following countries:

• Argentina

International Drug Name Search

Lidoderm

Lidoderm is a brand name of lidocaine topical, approved by the FDA in the following formulation(s):

LIDODERM (lidocaine - patch; topical)

• 
  Manufacturer: TEIKOKU PHARMA USA
  
  Approval date: March 19, 1999
  
  Strength(s): 5% ^[RLD]

Has a generic version of Lidoderm been approved?

No. There is currently no therapeutically equivalent version of Lidoderm available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lidoderm. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine
  Patent 5,411,738
  Issued: May 2, 1995
  Inventor(s): Hind; Harry
  Assignee(s): Hind Health Care, Inc.
  Methods and compositions are offered for reducing nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia), where intradermal delivery of lidocaine is maintained for a predetermined period of time. The lidocaine appears to specifically affect the damaged nerve fibers, while leaving the undamaged and normal nerve fibers with retention of response to other stimuli. Lidocaine formulations are provided which allow for the necessary dosage of the lidocaine in the dermis during the period of treatment. The formulation may be covered with an occlusive or non-occlusive dressing, which protects the lidocaine formulation from mechanical removal and enhances the transport of the lidocaine into the dermis. Long term relief is realized after maintenance of the administration of lidocaine has been terminated.
  
  Patent expiration dates:
  
  
  • May 2, 2012
    
  
  



• 
  Method for treating pain associated with herpes-zoster and post-herpetic neuralgia
  Patent 5,601,838
  Issued: February 11, 1997
  Inventor(s): Hind; Harry
  Assignee(s): Hind Health Care, Inc.
  A method is offered for reducing the pain associated with herpes-zoster and post-herpetic neuralgia. The method consists of administering a composition incorporating a transdermal delivery system for the administration of Lidocaine to areas of the body afflicted by herpes-zoster and post-herpetic neuralgia enclosed with an occlusive dressing or a plaster dressing.
  
  Patent expiration dates:
  
  
  • May 2, 2012
    
    ✓ 
    Patent use: METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA
  
  



• 
  Adhesive patch for applying analgesic medication to the skin
  Patent 5,741,510
  Issued: April 21, 1998
  Inventor(s): Rolf; David & Sjoblom Urmann; Elisabeth K.
  Assignee(s): Lectec Corporation
  A medication patch to be applied to the skin includes a self-supporting backing layer to give the patch the required integrity and strength by acting as a supporting framework for other components, and a flexible hydrophilic pressure-sensitive adhesive reservoir comprising a natural or synthetic polymer for the sustained release of medication to be absorbed topically through the skin into the body of a patient. The reservoir has two portions: first, an external coating layer with an exposed lower skin-contacting surface that forms a pressure-sensitive bond with the skin, and second, an upper internal portion which infiltrates the porous backing and becomes solidified therein after being applied so that the reservoir and the backing are unified, enabling the backing itself to act as a storage location for the medication-containing reservoir. The medication within the reservoir migrates over time from within the backing through the lower coating layer and passes through the skin to provide sustained release of the medication into the body of a patient.
  
  Patent expiration dates:
  
  
  • March 30, 2014
    
    ✓ 
    Drug product
  
  



• 
  External preparation for application to the skin containing lidocaine
  Patent 5,827,529
  Issued: October 27, 1998
  Inventor(s): Ono; Masahiro & Akazawa; Mitsuji & Seki; Michiko & Iwamoto; Kiyomi & Konishi; Ryoji
  Assignee(s): Teikoku Seiyaku Kabushiki Kaisha
  An external preparation for application to the skin containing lidocaine which comprises a drug-retaining layer placed on a support, wherein said drug-retaining layer comprises an adhesive gel base and 1 to 10% by weight of lidocaine, said base comprising a water-soluble high molecular weight substance, water and a water-retaining agent, which can release the active lidocaine gradually and constantly so that lidocaine is transdermally absorbed for a long period of time.
  
  Patent expiration dates:
  
  
  • October 27, 2015
    
    ✓ 
    Patent use: EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE
  
  

See also...

• Lidoderm Consumer Information (Drugs.com)
• Lidoderm Patch Consumer Information (Wolters Kluwer)
• Lidoderm Consumer Information (Cerner Multum)
• Lidoderm Topical application Advanced Consumer Information (Micromedex)
• Lidocaine Aerosol Consumer Information (Wolters Kluwer)
• Lidocaine Cream Consumer Information (Wolters Kluwer)
• Lidocaine Foam Consumer Information (Wolters Kluwer)
• Lidocaine Gel Consumer Information (Wolters Kluwer)
• Lidocaine Intradermal System Consumer Information (Wolters Kluwer)
• Lidocaine Liquid Consumer Information (Wolters Kluwer)
• Lidocaine Lotion Consumer Information (Wolters Kluwer)
• Lidocaine Ointment Consumer Information (Wolters Kluwer)
• Lidocaine Patch Consumer Information (Wolters Kluwer)
• Lidocaine Solution Consumer Information (Wolters Kluwer)
• Xylocaine Solution Consumer Information (Wolters Kluwer)
• Zilactin L Liquid Consumer Information (Wolters Kluwer)
• Zilactin-L Consumer Information (Cerner Multum)
• Lidocaine topical Consumer Information (Cerner Multum)
• Burn-O-Jel Topical application Advanced Consumer Information (Micromedex)
• Burnamycin Topical application Advanced Consumer Information (Micromedex)
• Solarcaine First Aid Lidocaine Spray Topical application Advanced Consumer Information (Micromedex)
• Solarcaine Lidocaine First Aid Spray Topical application Advanced Consumer Information (Micromedex)
• Xylocaine Topical application Advanced Consumer Information (Micromedex)
• Lidocaine Topical application Advanced Consumer Information (Micromedex)

Nesacaine-MPF

See also: Generic Nesacaine

Nesacaine-MPF is a brand name of chloroprocaine, approved by the FDA in the following formulation(s):

NESACAINE-MPF (chloroprocaine hydrochloride - injectable; injection)

• 
  Manufacturer: APP PHARMS
  
  Approval date: May 2, 1996
  
  Strength(s): 2% ^[RLD][AP], 3% ^[RLD][AP]

Has a generic version of Nesacaine-MPF been approved?

Yes. The following products are equivalent to Nesacaine-MPF:

chloroprocaine hydrochloride injectable; injection

• 
  Manufacturer: BEDFORD
  
  Approval date: September 9, 1998
  
  Strength(s): 2% ^[AP], 3% ^[AP]


• 
  Manufacturer: HOSPIRA
  
  Approval date: April 16, 1982
  
  Strength(s): 2% ^[AP], 3% ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nesacaine-MPF. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Nesacaine-MPF.

See also...

Interferon omega

In some countries, this medicine may only be approved for veterinary use.

Therapeutic Categories

Antiviral agent

Biological response modifier, BRM

Immunostimulant

Chemical Name

recombinant interferon omega, feline origin

Foreign Names

• Interferon omega (German)
• Interféron oméga (French)

Generic Name

• IFN Omega (IS)

Brand Names

• Virbagen (veterinary use)
  Biofarm, Finland; Virbac, Australia; Virbac, Belgium; Virbac, Switzerland; Virbac, Germany; Virbac, France; Virbac, Italy; Virbac, New Zealand

International Drug Name Search

Glossary

IS	Inofficial Synonym

Click for further information on drug naming conventions and International Nonproprietary Names.

Magnespasmyl

Magnespasmyl may be available in the countries listed below.

Ingredient matches for Magnespasmyl

Magnesium Lactate

Magnesium Lactate is reported as an ingredient of Magnespasmyl in the following countries:

• Belgium

International Drug Name Search

Eloxatin

Eloxatin is a brand name of oxaliplatin, approved by the FDA in the following formulation(s):

ELOXATIN (oxaliplatin - injectable; iv (infusion))

• 
  Manufacturer: SANOFI AVENTIS US
  
  Approval date: January 31, 2005
  
  Strength(s): 100MG/20ML (5MG/ML) ^[RLD][AP], 50MG/10ML (5MG/ML) ^[RLD][AP]


• 
  Manufacturer: SANOFI AVENTIS US
  
  Approval date: November 17, 2006
  
  Strength(s): 200MG/40ML (5MG/ML) ^[RLD]

Has a generic version of Eloxatin been approved?

A generic version of Eloxatin has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Eloxatin and have been approved by the FDA:

oxaliplatin injectable; iv (infusion)

• 
  Manufacturer: EBEWE PHARMA
  
  Approval date: August 7, 2009
  
  Strength(s): 100MG/20ML (5MG/ML) ^[AP], 50MG/10ML (5MG/ML) ^[AP]


• 
  Manufacturer: FRESENIUS KABI ONCOL
  
  Approval date: June 10, 2010
  
  Strength(s): 100MG/20ML (5MG/ML) ^[AP], 50MG/10ML (5MG/ML) ^[AP]


• 
  Manufacturer: HOSPIRA WORLDWIDE
  
  Approval date: August 7, 2009
  
  Strength(s): 100MG/20ML (5MG/ML) ^[AP], 50MG/10ML (5MG/ML) ^[AP]


• 
  Manufacturer: SANDOZ
  
  Approval date: January 24, 2011
  
  Strength(s): 100MG/20ML (5MG/ML) ^[AP], 50MG/10ML (5MG/ML) ^[AP]


• 
  Manufacturer: TEVA PARENTERAL
  
  Approval date: August 7, 2009
  
  Strength(s): 100MG/20ML (5MG/ML) ^[AP], 50MG/10ML (5MG/ML) ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Eloxatin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Platinum compound and process of preparing same
  Patent 5,290,961
  Issued: March 1, 1994
  Inventor(s): Okamoto; Koji & Hoshi; Yuko & Nakanishi; Chihiro
  Assignee(s): Tanaka Kikinzoku Kogyo K.K.
  Disclosed herein are a platinum compound employed as raw material of medicines having carcinostatic effects, and a process of preparing the platinum compound. The platinum compound (I) substantially free from impurities can be prepared through a reaction between the corresponding dihalogen compound and an organic dibasic acid employing an iodine compound utilizing the difference of solubilities between the desired compound and the iodine compounds.
  
  Patent expiration dates:
  
  
  • January 12, 2013
    
    ✓ 
    Drug substance
  
  
  
  • July 12, 2013
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) having optically high purity
  Patent 5,338,874
  Issued: August 16, 1994
  Inventor(s): Nakanishi; Chihiro & Ohnishi; Yuko & Ohnishi; Junji & Taniuchi; Junichi & Okamoto; Koji & Tozawa; Takeshi
  Assignee(s): Tanaka Kikinzoku Kogyo K.K.
  Disclosed herein is cis-oxalato (trans-1-1,2-cyclohexanediamine) Pt(II) optically high purity. Because of its complete optical purity, the compound is effective as raw material of such a medicine as a carcinostatic agent. The complete optical purity of the above compound may be proved by comparing the respective melting points of the cis-oxalato (trans-1-1,2-cyclohexanediamine).
  
  Patent expiration dates:
  
  
  • April 7, 2013
    
    ✓ 
    Drug substance
  
  
  
  • October 7, 2013
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and process of preparing same
  Patent 5,420,319
  Issued: May 30, 1995
  Inventor(s): Okamoto; Koji & Nakanishi; Chihiro & Taniuchi; Junichi & Ohnishi; Junji & Komoda; Yasunobu
  Assignee(s): Tanaka Kikinzoku Kogyo K.K.
  Disclosed is cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and no toxicity and exhibiting anticancer performance, as shown in the below Formula. Cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex of the invention possesses high optical purity or 99.94% or more e.e. and a melting point of 198.3.degree. to 199.7.degree. C. The complex is synthesized employing as starting material trans-1-1,2-cyclohexamediamine or a derivative of the trans-1-1,2-cyclohexanediamine optically resoluted by means of a high performance liquid chromatography. ##STR1##
  
  Patent expiration dates:
  
  
  • August 9, 2016
    
    ✓ 
    Drug substance
  
  
  
  • February 9, 2017
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutically stable preparation of oxaliplatinum
  Patent 5,716,988
  Issued: February 10, 1998
  Inventor(s): Ibrahim; Houssam & Mauvernay; Rolland-Yves
  Assignee(s): Debiopharm S.A.
  A pharmaceutically stable oxaliplatinum preparation for parenteral administration comprises an aqueous solution of oxaliplatinum, in a concentration of 1 to 5 mg/ml, and with a pH in the range of 4.5 to 6. The aqueous oxaliplatinum solution is advantageously provided as a ready-to-use preparation in a sealed container.
  
  Patent expiration dates:
  
  
  • August 7, 2015
    
    ✓ 
    Drug product
  
  
  
  • February 7, 2016
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • July 10, 2010 - PEDIATRIC EXCLUSIVITY
  
  

See also...

• Eloxatin Consumer Information (Drugs.com)
• Eloxatin Consumer Information (Wolters Kluwer)
• Eloxatin Consumer Information (Cerner Multum)
• Eloxatin Advanced Consumer Information (Micromedex)
• Eloxatin AHFS DI Monographs (ASHP)
• Oxaliplatin Consumer Information (Wolters Kluwer)
• Oxaliplatin Consumer Information (Cerner Multum)
• Oxaliplatin Intravenous Advanced Consumer Information (Micromedex)
• Oxaliplatin AHFS DI Monographs (ASHP)

Nebivolol AAA

Nebivolol AAA may be available in the countries listed below.

Ingredient matches for Nebivolol AAA

Nebivolol

Nebivolol hydrochloride (a derivative of Nebivolol) is reported as an ingredient of Nebivolol AAA in the following countries:

• Germany

International Drug Name Search

Erilin

Erilin may be available in the countries listed below.

Ingredient matches for Erilin

Sildenafil

Sildenafil citrate (a derivative of Sildenafil) is reported as an ingredient of Erilin in the following countries:

• Colombia

International Drug Name Search

Cefonicid Sodium

Cefonicid Sodium may be available in the countries listed below.

Ingredient matches for Cefonicid Sodium

Cefonicid

Cefonicid Sodium (BANM, USAN) is known as Cefonicid in the US.

International Drug Name Search

Glossary

BANM	British Approved Name (Modified)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Embeda

Embeda is a brand name of morphine/naltrexone, approved by the FDA in the following formulation(s):

EMBEDA (morphine sulfate; naltrexone hydrochloride - capsule, extended release; oral)

• 
  Manufacturer: ALPHARMA KING
  
  Approval date: August 13, 2009
  
  Strength(s): 100MG;4MG ^[RLD], 20MG;0.8MG, 30MG;1.2MG, 50MG;2MG, 60MG;2.4MG, 80MG;3.2MG
  

Has a generic version of Embeda been approved?

No. There is currently no therapeutically equivalent version of Embeda available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Embeda. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pharmaceutical composition
  Patent 7,682,633
  Issued: March 23, 2010
  Inventor(s): Matthews; Frank & Boehm; Garth & Tang; Lijuan & Liang; Alfred
  Assignee(s): Alpharma Pharmaceuticals, LLC
  Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.
  
  Patent expiration dates:
  
  
  • June 19, 2027
    
    ✓ 
    Patent use: MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
  
  



• 
  Pharmaceutical compositions
  Patent 7,682,634
  Issued: March 23, 2010
  Inventor(s): Matthews; Frank & Boehm; Garth & Tang; Lijuan & Liang; Alfred
  Assignee(s): Alpharma Pharmaceuticals, LLC
  Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.
  
  Patent expiration dates:
  
  
  • June 19, 2027
    
    ✓ 
    Drug product
  
  



• 
  Sequestering subunit and related compositions and methods
  Patent 7,815,934
  Issued: October 19, 2010
  Inventor(s): Boehm; Garth
  Assignee(s): Alpharma Pharmaceuticals, LLC
  A sequestering subunit comprising an aversive agent and a blocking agent, wherein the blocking agent substantially prevents release of the aversive agent from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours; a composition comprising a sequestering subunit and a therapeutic agent in releasable form, wherein, optionally, the mechanical fragility of the sequestering subunit is the same as the mechanical fragility of the therapeutic agent in releasable form; a capsule or tablet comprising a sequestering subunit and a therapeutic agent; and a method of preventing abuse of a therapeutic agent.
  
  Patent expiration dates:
  
  
  • December 12, 2027
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • August 13, 2012 - NEW COMBINATION
  
  

See also...

• Embeda Consumer Information (Drugs.com)
• Embeda Extended-Release Capsules Consumer Information (Wolters Kluwer)
• Embeda Consumer Information (Cerner Multum)
• Embeda Advanced Consumer Information (Micromedex)
• Morphine/Naltrexone Extended-Release Capsules Consumer Information (Wolters Kluwer)
• Morphine and naltrexone Consumer Information (Cerner Multum)
• Morphine and naltrexone Advanced Consumer Information (Micromedex)

Zopiclona Genfar

Zopiclona Genfar may be available in the countries listed below.

Ingredient matches for Zopiclona Genfar

Eszopiclone

Zopiclone is reported as an ingredient of Zopiclona Genfar in the following countries:

• Colombia

International Drug Name Search